The new UK SARS-CoV-2 variant and lockdown - causes and consequences.
SARS-CoV-2
immunosuppression
lockdown
new variant
vaccination
Journal
Clinical medicine (London, England)
ISSN: 1473-4893
Titre abrégé: Clin Med (Lond)
Pays: England
ID NLM: 101092853
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
pubmed:
8
4
2021
medline:
21
5
2021
entrez:
7
4
2021
Statut:
ppublish
Résumé
The new variant of concern (VOC), B.1.1.7, has a distinct set of mutations in nucleotides encoding the spike (S) protein on the surface of SARS-CoV-2. SARS-CoV-2 previously accumulated mutations at a much slower rate, of 1-2 per month; the sudden appearance of a large cluster of mutations was thought to be unusual. We now suspect that VOC may have arisen from immunosuppressed individuals who shed virus for longer periods. Epidemiological analyses estimate VOC to be more infectious; this is of most concern because these estimates were calculated during periods where many regions of the UK were in high social distancing restrictions. Therefore, the previous 'tiered' system implemented in the UK was ineffective at containing VOC. The most likely reason for this is that previous restrictions, no matter how strict, still allowed for gatherings in certain places. VOC also has implications for the national vaccination programme - a higher proportion of people will need to be vaccinated with a more infectious virus. Prolongation of the second dose of vaccines to increase vaccine uptake has understandably caused concern, but is based on sound immunological principles. There is now an urgent need to monitor the effect of new variants on vaccine efficacy - marking a new chapter in the global fight against COVID-19.
Identifiants
pubmed: 33824139
pii: clinmed.2021-0019
doi: 10.7861/clinmed.2021-0019
pmc: PMC8140690
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e295-e299Informations de copyright
© Royal College of Physicians 2021. All rights reserved.
Références
EClinicalMedicine. 2020 Dec;29:100630
pubmed: 33200120
Cell. 2020 Dec 23;183(7):1901-1912.e9
pubmed: 33248470
Virus Evol. 2020 Aug 19;6(2):veaa061
pubmed: 33235813
MMWR Morb Mortal Wkly Rep. 2020 May 15;69(19):606-610
pubmed: 32407303
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Infect Dis. 2021 Jan 4;223(1):23-27
pubmed: 33089317
JAMA Intern Med. 2020 Dec 1;180(12):1665-1671
pubmed: 32870239
Lancet Microbe. 2021 Jan;2(1):e13-e22
pubmed: 33521734
N Engl J Med. 2020 Dec 3;383(23):2291-2293
pubmed: 33176080
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246